Juul Agrees To Settle Thousands Of Vaping Lawsuits

Read about the biggest pharmaceutical developments and pricing stories from the past week in KHN’s Prescription Drug Watch roundup.


Bloomberg:
Juul Says It’s Settling More Than 5,000 Youth Vaping Lawsuits 


Juul Labs Inc. reached a settlement of more than 5,000 lawsuits blaming the company for a youth vaping epidemic across the US. As part of the accord, the embattled e-cigarette maker isn’t allowed to immediately disclose the settlement amount, the company said in a statement, adding that the accord will be funded with an equity investment. (Nayak, 12/7)

In other legal developments —

More pharmaceutical news —


Stat:
Eli Lilly Tightens Access To Diabetes Drug, Frustrating Obesity Patients


Touted by celebrities, raved about by TikTok users and advertised by med spas, a new class of drugs for treating diabetes and obesity has exploded in popularity for its weight-loss effects, leading to rippling shortages across several of the medications. Amid the surge in demand, Eli Lilly and pharmacies have started to tighten access to the latest of this type of drug, tirzepatide, focusing on giving it to people with type 2 diabetes, the only population it’s authorized for so far. (Chen, 12/7)

Also —

Perspectives: Breakthrough Therapy Act Is Flawed; Texas Made Right Decision On Fentanyl Testing Strips

Read recent commentaries about drug-cost issues.


Stat:
Breakthrough Therapies Act: Good Idea, Wrong Solution 


The Breakthrough Therapies Act, recently proposed by Senators Rand Paul (R-Ky.) and Cory Booker (D-N.J.) as a way to expand access for therapeutic purposes to potentially beneficial but highly regulated Schedule I substances like psilocybin and LSD, has the right underlying idea but provides a solution that is wrong. (Arthur L. Caplan and Kenneth I. Moch, 12/2)


Houston Chronicle:
Abbott’s Big Flip-Flop On Fentanyl Could Save Lives


For too long, many believed that fentanyl wasn’t a Texas problem. “There’s no sense of urgency,” paramedic Daniel Sledge complained to the Chronicle last year. As one of the people who saw the drug’s deadly impacts on the state, he knew better than most the damage the potent, highly addictive drug could do. (12/3)

link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *